ProfileGDS5678 / 1441342_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 33% 34% 35% 42% 32% 38% 33% 34% 32% 33% 34% 34% 34% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7948933
GSM967853U87-EV human glioblastoma xenograft - Control 22.7615634
GSM967854U87-EV human glioblastoma xenograft - Control 32.7938735
GSM967855U87-EV human glioblastoma xenograft - Control 42.9157242
GSM967856U87-EV human glioblastoma xenograft - Control 52.6837132
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.966238
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7923633
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7501134
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7046632
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7412733
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7561134
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7435734
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7660934
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7583634